Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously

blonca9
Sep 24, 2024
1 min read

Acting CEO Dragan Grabulovski describes how they are able to achieve this, the benefits of having multiple payload classes at once, and the targets the company is currently working on.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight